6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
A series of 6alpha-alkyl-substituted analogues of chenodeoxycholic acid (CDCA) were synthesized and evaluated as potential farnesoid X receptor (FXR) ligands. Among them, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA) was shown to be a very potent and selective FXR agonist (EC(50) = 99 nM) and to be endowed with anticholeretic activity in an in vivo rat model of cholestasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A bile acid receptor (FXR) agonist has reached the market since this programme started: obeticholic acid (Ocaliva), which was discovered by GSK in collaboration with the University of Perugia51 and subsequently developed by Intercept Pharmaceuticals.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [51]
In the citing paper
“OCA is a farnesoid X receptor (FXR) agonist that is 100 times more potent than the endogenous ligand, chenodeoxycholic acid.(156)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [156]
In the citing paper
“Obeticholic acid has approximately 100 times greater potency in activating FXR than chenodeoxycholic acid. 11”
From A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis (2016) · cites this paper as [11]
In the citing paper
“Obeticholic acid is a selective farnesoid X receptor (FXR) agonist that is derived from the bile acid chenodeoxycholic acid, the endogenous FXR ligand.”
From A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis (2016) · cites this paper as [11]
In the citing paper
“OCA, a 6α-ethyl derivate of chenodeoxycholic acid, is a steroidal FXR agonist (still maintaining its BA structure) and first-in-class therapeutic FXR ligand.94”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [94]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Identification of a nuclear receptor for bile acids
Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
Self-citationNuclear Receptors and Lipid Physiology: Opening the X-Files
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001) · Science · doi:10.1126/science.294.5548.1866 · Cited by 2,085
A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis
Goodwin, B., Jones, S. A., Price, R. R., Watson, M. A., McKee, D. D., Moore, L. B., Galardi, C., Wilson, J. G., Lewis, M. C., Roth, M. E., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00051-4 · Cited by 1,940
Self-citationTargeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR
Wang, H., Chen, J., Hollister, K., Sowers, L. C., & Forman, B. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80348-2 · Cited by 1,636
Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators
McKenna, N. J., & O'Malley, B. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00641-4 · Cited by 1,463
The Continuing Importance of Bile Acids in Liver and Intestinal Disease
Hofmann, A. F. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.22.2647 · Cited by 982
Modulation of Polyketide Synthase Activity by Accessory Proteins During Lovastatin Biosynthesis
Kennedy, J., Auclair, K., Kendrew, S. G., Park, C., Vederas, J. C., & Richard Hutchinson, C. (1999) · Science · doi:10.1126/science.284.5418.1368 · Cited by 654
Identification of a Chemical Tool for the Orphan Nuclear Receptor FXR
Maloney, P. R., Parks, D. J., Haffner, C. D., Fivush, A. M., Chandra, G., Plunket, K. D., Creech, K. L., Moore, L. B., Wilson, J. G., Lewis, M. C., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0002127 · Cited by 527
Self-citation
Research works printed but not linked: 3
- Mangelsdorf D. J., 1995, Cell, 83, 850
- Forman B. M., 1995, Cell, 81, 693
- Lu T. T., 2000, Mol. Cell, 6, 515
Cited by
Items 501–600 of 793
Development of NR0B2 as a therapeutic target for the re-education of tumor associated myeloid cells
Vidana Gamage, H. E., Albright, S. T., Smith, A. J., Farmer, R., Shahoei, S. H., Wang, Y., Fink, E. C., Jacquin, E., Weisser, E., Bautista, R. O., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217086 · Cited by 13
“The assay was validated by testing two known FXR agonists which would be expected to upregulate NR0B2: GW4064 a synthetic agonist, and obeticholic acid, a semisynthetic bile acid [27,28].”
Fast chromatographic determination of the bile salt critical micellar concentration
Natalini, B., Sardella, R., Gioiello, A., Rosatelli, E., Ianni, F., Camaioni, E., & Pellicciari, R. (2011) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-011-5082-4 · Cited by 13
Self-citationStructural Insight into the Binding Mode of FXR and GPBAR1 Modulators
Leva, F. S. D., Marino, D. D., & Limongelli, V. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_234 · Cited by 15
Obeticholic acid improves fetal bile acid profile in a mouse model of gestational hypercholanemia
Pataia, V., McIlvride, S., Papacleovoulou, G., Ovadia, C., McDonald, J. A. K., Wahlstrom, A. M., Jansen, E. H. J. M., Adorini, L., Shapiro, D., Marchesi, J. R., et al. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00126.2020 · Cited by 15
An Update on the Treatment and Follow-up of Patients with Primary Biliary Cholangitis
Burman, B. E., Jhaveri, M. A., & Kowdley, K. V. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.06.005 · Cited by 13
Douša, M., Slavíková, M., Kubelka, T., Černý, J., Gibala, P., & Zezula, J. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.11.018 · Cited by 13
The Physiological Importance of Bile Acid Structure and Composition on Glucose Homeostasis
Higuchi, S. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01329-5 · Cited by 13
Bile Acids and the Enterohepatic Circulation
Hofmann, A. F. (2009) · Wiley eBooks · doi:10.1002/9780470747919.ch20 · Cited by 17
Bile acids in metabolic dysfunction-associated steatotic liver disease
Zerem, E., Kunosić, S., Kurtčehajić, A., Zerem, D., & Zerem, O. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i8.108606 · Cited by 18
Weak Microbial Metabolites: a Treasure Trove for Using Biomimicry to Discover and Optimize Drugs
Dvořák, Z., Klapholz, M., Burris, T. P., Willing, B. P., Gioiello, A., Pellicciari, R., Galli, F., March, J. C., O’Keefe, S. J., Sartor, R. B., et al. (2020) · Molecular Pharmacology · doi:10.1124/molpharm.120.000035 · Cited by 12
Self-citationThe discovery of 12β-methyl-17-epi-18-nor-bile acids as potent and selective TGR5 agonists
Luxenburger, A., Harris, L. D., Ure, E. M., Jiao, W., Woolhouse, A. D., Cameron, S. A., Weymouth‐Wilson, A., Furneaux, R. H., Pitman, J. L., & Hinkley, S. F. R. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115143 · Cited by 14
Patented Farnesoid X receptor modulators: a review (2019 – present)
Gioiello, A., Rosatelli, E., & Cerra, B. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2314296 · Cited by 14
A Nurr1 Agonist Derived from the Natural Ligand DHI Induces Neuroprotective Gene Expression
Egner, M., Busch, R., López-García, Ú., Lewandowski, M., Höfner, G. C., Wein, T., Marschner, J. A., & Merk, D. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03104 · Cited by 13
Ferrigno, A., Pasqua, L. G. D., Berardo, C., Siciliano, V., Rizzo, V., Adorini, L., Richelmi, P., & Vairetti, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191430 · Cited by 11
Mawardi, M., Alalwan, A. M., Fallatah, H. I., Abaalkhail, F. A., Hasosah, M. Y., Shagrani, M. A., Alghamdi, M., & Alghamdi, A. (2021) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_112_21 · Cited by 14
“[56] In comparison to chenodeoxycholic acid, FXR is effectively activated by OCA.”
BackgroundLi, R., Hovingh, M. V., Koehorst, M., de Blaauw, P., Verkade, H. J., de Boer, J. F., & Kuipers, F. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159163 · Cited by 12
Discovery of 9,11-Seco-Cholesterol Derivatives as Novel FXR Antagonists
Zhou, J.-X., Li, C.-N., Liu, Y., Lin, S., Wang, Y., Xie, C., & Nan, F. (2022) · ACS Omega · doi:10.1021/acsomega.2c01567 · Cited by 14
Yuan, Z., Wang, J., Zhang, H., Miao, Y., Tang, Q., Yuan, Z., Nong, C., Duan, Z., Zhang, L., Jiang, Z., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1032722 · Cited by 12
Ferrigno, A., Palladini, G., Pasqua, L. G. D., Berardo, C., Richelmi, P., Cadamuro, M., Fabris, L., Perlini, S., Adorini, L., & Vairetti, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238543 · Cited by 13
Weber, A. A., Mennillo, E., Yang, X., van der Schoor, L. W. E., Jonker, J. W., Chen, S., & Tukey, R. H. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000240 · Cited by 12
Development and in vitro Profiling of Dual FXR/LTA4H Modulators
Schierle, S., Brunst, S., Helmstädter, M., Ebert, R., Kramer, J. S., Steinhilber, D., Proschak, E., & Merk, D. (2021) · ChemMedChem · doi:10.1002/cmdc.202100118 · Cited by 12
The discovery of a new potent FXR agonist based on natural product screening
Yao, Z., Chen, L., Hu, M., Meng, F., Chen, M., & Wang, G. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106979 · Cited by 11
Structural Basis of Novel Bile Acid-Based Modulators of FXR
Kydd-Sinclair, D., Packer, G., Weymouth‐Wilson, A., & Watson, K. A. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169383 · Cited by 11
Molecular Targets for the Treatment of Fibrosing Cholangiopathies
Wenniger, L. J. M. D. B., Elferink, R. P. J. O., & Beuers, U. H. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.111 · Cited by 12
A new serotonin 2A receptor antagonist with potential benefits in Non-Alcoholic Fatty Liver Disease
Sessa, L., Concilio, S., Fominaya, J. M., Eletto, D., Piotto, S., & Busquets, X. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121315 · Cited by 12
Synthesis and antitumor activity of alkylated bile acids and oxazolines
Bjedov, S., Jakimov, D., Poša, M., Klisurić, O. R., & Sakač, M. N. (2017) · Tetrahedron · doi:10.1016/j.tet.2017.10.058 · Cited by 11
Miyazaki, T., Honda, A., Ikegami, T., Iida, T., & Matsuzaki, Y. (2018) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.18-80 · Cited by 12
Lehman, A. M. B., Montford, J. R., Horita, H. N., Ostriker, A. C., Weiser‐Evans, M. C. M., Nemenoff, R. A., & Furgeson, S. B. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.092163 · Cited by 13
“…acetic acid] (PPARa agonist) (Forman et al., 1997), pioglitazone (PPARg agonist) (Sakamoto et al., 2000), GW501516 (PPARd agonist) (Oliver et al., 2001), T0901317 (LXR agonist) (Repa et al., 2000), and 6-a-ethyl-chenodeoxycholic acid (6-ECDCA, FXR agonist) (Pellicciari et al., 2002).”
Potential therapeutic applications of farnesoid X receptor (FXR) modulators
Pellicciari, R., Gioiello, A., & Costantino, G. (2006) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.16.3.333 · Cited by 12
“The potential associated with a tuned chemical modification of the steroid endogenous natural ligand CDCA (1) is well exemplified by the discovery of 6α-ethyl-CDCA (6ECDCA INT-747; 14, Figure 4) as a high selective and potent (EC50 = 99 nM) FXR agonist [21,115,116].”
BackgroundSelf-citationThe association between total bile acid and bone mineral density among patients with type 2 diabetes
Yang, S. T., Li, H., Gu, Y., Wang, Q., Li, D., Xu, C., Fan, Y., Liu, M. R., Guan, Q., & Ma, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1153205 · Cited by 16
“First, TBA facilitates the differentiation of bone marrow mesenchymal cells into osteoblasts in vitro (33, 34).”
BackgroundXiong, A., Lu, L., Jiang, K., Wang, X., Chen, Y., Wang, X., Zhang, W., Zhuge, Y., Huang, W., Li, L., et al. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03762-x · Cited by 11
“OCA is a known FXR agonist (Pellicciari et al. 2002) and is FDA-approved for treatment of primary biliary cholangitis patients not responding or intolerant to UDCA (Nevens et al. 2016).”
Gu, J., Wu, Q., Zhang, Q., You, Q., & Wang, L. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114742 · Cited by 12
Obeticholic Acid—A Pharmacological and Clinical Review
Keshvani, C., Kopel, J. J., & Goyal, H. (2023) · Future Pharmacology · doi:10.3390/futurepharmacol3010017 · Cited by 12
Khalid, Q., Bailey, I., & Patel, V. B. (2015) · Liver Research - Open Journal · doi:10.17140/lroj-1-106 · Cited by 10
Giancristofaro, A., Barbosa, A. J. M., Ammazzalorso, A., Amoia, P., Filippis, B. D., Fantacuzzi, M., Giampietro, L., Maccallini, C., & Amoroso, R. (2018) · MedChemComm · doi:10.1039/c8md00272j · Cited by 10
Novel Therapies on Primary Biliary Cirrhosis
Czul, F., & Levy, C. (2015) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.08.006 · Cited by 12
“further repression of ASBT in the gut and inhibition of CYP7A1 in the hepatocyte, thus decreasing bile acid synthesis.(20) Therefore, by activating FXR, OCA reduces production of bile in the liver and increases bile flow in cholestatic conditions, thus protecting the hepatocytes from accumulation of cytotoxic bile aci…”
BackgroundEvolving therapeutic landscape of primary biliary cholangitis: A review
Mitchell, N. E., Chan, S., Diaz, D. J., Ansari, N., Lee, J. S., & Twohig, P. A. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i7.107223 · Cited by 11
“FXR serves as a key transcriptional regulator of bile acid metabolism and is predominantly expressed in the liver and intestine[13].”
Koelfat, K. V. K., Visschers, R. G. J., Hodin, C. M. I. M., de Waart, D. R., van Gemert, W. G., Cleutjens, J. P. M., Gijbels, M. J., Shiri‐Sverdlov, R., Mookerjee, R. P., Lenaerts, K., et al. (2017) · Journal of Clinical and Translational Research · doi:10.18053/jctres.03.201703.004 · Cited by 12
“The consequences of activation of FXR on drainage-induced liver damage were studied by administration of the potent FXR agonist INT-747 [23] In contrast to biliary fibrosis, histopathological scores of hepatic inflammation were significantly lower in drained animals receiving INT-747 (Figure 1B).”
BackgroundParés, A. R. (2015) · Digestive Diseases · doi:10.1159/000440761 · Cited by 9
Process Research and Impurity Control Strategy for Obeticholic Acid, a Farnesoid X Receptor Agonist
Feng, W.-D., Zhuo, S.-M., & Zhang, F. (2019) · Organic Process Research & Development · doi:10.1021/acs.oprd.9b00252 · Cited by 9
Synthesis of 12β-methyl-18- nor -avicholic acid analogues as potential TGR5 agonists
Ure, E. M., Harris, L. D., Cameron, S. A., Weymouth‐Wilson, A., Furneaux, R. H., Pitman, J. L., Hinkley, S. F. R., & Luxenburger, A. (2022) · Organic & Biomolecular Chemistry · doi:10.1039/d1ob02401a · Cited by 9
Kauffman, J. M., Pellicciari, R., & Carey, M. C. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400439-jlr200 · Cited by 9
Self-citationWang, L., Si, P., Sheng, Y., Chen, Y., Wan, P., Shen, X., Tang, Y., Chen, L., & Li, W. (2014) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12432 · Cited by 10
“To date, a variety of compounds have been identified to be able to potently activate FXR, including 6ECDCA (16), MFA-1 (17), GW4064 (18), fexaramine (19), XL335 (20), and antiparasitic drug ivermectin (21).”
BackgroundSide‐chain modified bile acids: chromatographic separation of 23‐methyl epimers
Natalini, B., Sardella, R., Gioiello, A., Carbone, G., Dawgul, M. A., & Pellicciari, R. (2009) · Journal of Separation Science · doi:10.1002/jssc.200900080 · Cited by 9
Self-citationComputational Insight into the Allosteric Activation Mechanism of Farnesoid X Receptor
Chen, Y., Li, J., Wu, Z., Liu, G., Li, H., Tang, Y., & Li, W. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00914 · Cited by 9
Zhang, T., Dong, X., & Chen, M. (2006) · Journal of Chemical Information and Modeling · doi:10.1021/ci060112v · Cited by 9
Wang, J., Ma, L., An, Y., Ge, Y., Xu, D., & Mao, E. (2025) · Pharmaceuticals · doi:10.3390/ph18050763 · Cited by 10
“Obeticholic acid (OCA), also referred to as 6-ethyl-chenodeoxycholic acid, is a potent semisynthetic CDCA-derived FXR agonist [29].”
Therapeutic advances for primary biliary cholangitis: the old and the new
Wang, L., Zhang, F., & Zhang, X. (2016) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000591 · Cited by 11
Asgharpour, A., Dinani, A. M., & Friedman, S. L. (2020) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2020.01.04 · Cited by 10
“These emerging roles of bile acids as signaling molecules have been exploited for clinical use through the development of synthetic ligands that activate nuclear receptors, in particular the farnesoid X receptor (FXR) Among FXR ligands, 6-ethyl chenodeoxycholic acid (6-ECDCA), more commonly known as obeticholic acid (…”
Gohda, K., Iguchi, Y., Masuda, A., Fujimori, K., Yamashita, Y., & Teno, N. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128026 · Cited by 9
Heering, J., Jores, N., Kilu, W., Schallmayer, E., Peelen, E., Muehler, A. R., Kohlhof, H., Vitt, D., Linhard, V. L., Gande, S. L., et al. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00599 · Cited by 11
Zivko, C., Witt, F., Koeberle, A., Fuhrmann, G., & Luciani, P. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.11.025 · Cited by 8
“OA , on the other hand, is a semi-synthetic analogue of bile acid, a potent agonist (EC 50 = 99 nM) of the FXR, a nuclear hormone receptor of key importance in the regulation of bile acid homeostasis and hepatic metabolism [32], and the first such drug used in human clinical studies [33,34].”
Sohal, A., & Kowdley, K. V. (2023) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s361077 · Cited by 9
“Obeticholic acid is derived from chenodeoxycholic acid and imparts 100 times the increased agonism for the farnesoid X receptor (FXR) than endogenous chenodeoxycholic acid.(58) FXR activation inhibits the transcription of CYP7A1, which decreases the synthesis of bile acids.”
BackgroundNuclear Receptor Modulators — Current Approaches and Future Perspectives
Kronenberger, T., Keminer, O., Wrenger, C., & Windshügel, B. (2015) · InTech eBooks · doi:10.5772/59666 · Cited by 10
Regulation of Hepatobiliary Transporters during Liver Injury
Manautou, J. E., Campion, S. N., & Aleksunes, L. M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.01008-3 · Cited by 10
Steri, R., Schneider, P., Klenner, A., Rupp, M., Kriegl, J. M., Schubert‐Zsilavecz, M., & Schneider, G. (2010) · Molecular Informatics · doi:10.1002/minf.200900009 · Cited by 8
Nuclear receptors: how do they position in non‐alcoholic fatty liver disease treatment?
Machado, M. V., & Cortez‐Pinto, H. (2014) · Liver International · doi:10.1111/liv.12578 · Cited by 9
Primary biliary cirrhosis: safety and benefits of established and emerging therapies
Tabibian, J. H., & Lindor, K. D. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1073260 · Cited by 9
“OCA, as a result of the 6-a ethyl substitution, is nearly a 100-fold more potent agonist of FXR than CDCA, whereas UDCA, although an epimer of CDCA, lacks meaningful FXR activity [28,32].”
BackgroundGitto, S., Guarneri, V., Sartini, A., & Andreoné, P. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1399060 · Cited by 9
“Notably, OCA shows 100 times more potency in activating FXR than chenodeoxycholic acid [12].”
BackgroundŠtefela, A., Kašpar, M., Drastík, M., Holas, O., Hroch, M., Smutný, T., Škoda, J., Hutníková, M., Pandey, A. V., Mičuda, S., et al. (2020) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2020.105702 · Cited by 8
Investigational drugs in early phase development for primary biliary cholangitis
Gochanour, E. M., & Kowdley, K. V. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1857364 · Cited by 9
Synthesis of 12β-Methyl-18-nor-bile Acids
Luxenburger, A., Harris, L. D., Ure, E. M., Aponte, R. A. L., Woolhouse, A. D., Cameron, S. A., Ling, C. D., Piltz, R. O., Lewis, A. R., Gainsford, G. J., et al. (2021) · ACS Omega · doi:10.1021/acsomega.1c04199 · Cited by 8
Song, K., Xu, X. Y., Liu, P., Chen, L., Shen, X., Liu, J., & Hu, L. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.08.021 · Cited by 8
Obeticholic acid in primary biliary cholangitis
Erlinger, S. (2016) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2016.09.006 · Cited by 9
3D-QSAR studies with the aid of molecular docking for a series of non-steroidal FXR agonists
Zhang, T., Zhou, J., Shi, L., Zhu, R., & Chen, M. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.01.079 · Cited by 8
Nuclear Receptor Interdomain Communication is Mediated by the Hinge with Ligand Specificity
Hazarika, S., Yu, T., Biswas, A., Dube, N., Villalona, P., & Okafor, C. D. (2024) · Journal of Molecular Biology · doi:10.1016/j.jmb.2024.168805 · Cited by 7
Transcriptional Control of Trpm6 by the Nuclear Receptor FXR
Kim, E. Y., & Lee, J. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23041980 · Cited by 9
“Among them, obeticholic acid (OCA), a semisynthetic chenodeoxycholic aid (also known as 6α-ethyl-chenodeoxycholic acid or INT-747), is about 100-fold more potent than chenodeoxycholic acid (CDCA) and has been approved to treat primary biliary cholangitis despite pruritis as a side effect for some patients [34,35].”
BackgroundSodium cholate ameliorates nonalcoholic steatohepatitis by activation of FXR signaling
Pan, L., Yu, Z., Liang, X., Yao, J., Fu, Y., He, X., Ren, X., Chen, J., Li, X., Lu, M.-Q., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000039 · Cited by 8
“[37,38] Obeticholic acid (OCA) is a selective FXR agonist with anticholestatic and hepatoprotective properties,[39] participating in BA anabolism and enterohepatic circulation, and modulate immune inflammatory and fibrotic.”
BackgroundMolecular Pathways Governing the Termination of Liver Regeneration
de Haan, L. R., van Golen, R. F., & Heger, M. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.000955 · Cited by 11
New Chemical Entities Entering Phase III Trials in 2012
Notte, G. T. (2013) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-417150-3.00027-2 · Cited by 7
Zhang, Y., Jiang, Q., Liu, X., Peng, L., Tang, X., Li, L., Ling, X., Yang, X., He, C., Tao, X., et al. (2021) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2021.3173 · Cited by 7
Aishwarya, T. S., Mounika, N., Vishwakarma, G., & Adela, R. (2022) · RPS Pharmacy and Pharmacology Reports · doi:10.1093/rpsppr/rqac001 · Cited by 8
Zhu, Y., Li, G., Dong, Y., Zhou, H. H., Kong, B., Aleksunes, L. M., Richardson, J. R., Li, F., & Guo, G. L. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.11.012 · Cited by 8
“INT-747 is a derivative of chenodeoxycholic acid (CDCA) and is potent in activating FXR (Pellicciari et al., 2002).”
BackgroundThe Discovery of Obeticholic Acid ( Ocaliva™ ): First‐in‐Class FXR Agonist
Pellicciari, R., Pruzanski, M., & Gioiello, A. (2018) · Wiley eBooks · doi:10.1002/9783527808694.ch8 · Cited by 12
Self-citationRosatelli, E., Carotti, A., Cerra, B., Franco, F., Passeri, D., Pellicciari, R., & Gioiello, A. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115851 · Cited by 6
Self-citationEnhanced dynamic coupling in a nuclear receptor underlies ligand activity
Yu, T., Villalona, P., Khan, S. H., Mikeasky, N., Meinert, E., Magafas, J., Pulahinge, T., Bader, A., & Okafor, C. D. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.108081 · Cited by 6
Future potential therapeutics to treat MASH
Mahajan, S., Malladi, N., & Banerjee, S. K. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104451 · Cited by 10
Wang, Y., Zhu, Y., Niu, J., Deng, Q., Guo, S., Jiang, H., Peng, Z., Xue, Y., Peng, H., Xuan, L., et al. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115169 · Cited by 6
FXR agonists for colorectal and liver cancers, as a stand-alone or in combination therapy
Yu, D., Lu, Z., Wang, R., Xiang, Y., Li, H., Lu, J., Zhang, L., Chen, H., Li, W., Luan, X., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115570 · Cited by 7
Jiang, Y., Fang, Z., Guthrie, G. J., Stoll, B., Chacko, S. K., Lin, S., Hartmann, B., Holst, J. J., Dawson, H. D., Pastor, J. J., et al. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100919 · Cited by 6
“Indeed, OCA is an analog of CDCA, with 100-fold higher NR1H4 activation potency (99 nM for OCA vs. 8.66 μ M for CDCA) (29).”
InfluentialEvidence-Based Treatment of Primary Biliary Cirrhosis
Poupon, R. Y. (2014) · Digestive Diseases · doi:10.1159/000360516 · Cited by 7
Kim, E. Y., & Lee, J. M. (2022) · Antioxidants · doi:10.3390/antiox11020370 · Cited by 8
“At the same time, these cells were co-treated with or without synthetic FXR agonist ligands GW4064 [32] or obeticholic acid (OCA, also known as INT-747 or 6α-ethyl-chenodeoxycholic acid) [33] (Figure 1c).”
BackgroundCytotoxic Effect of 6-Ethyl-Chenodeoxycholic Acid and Cabazitaxel on PC-3 Cells
Zalzala, M. H., Al-khfajy, W. S., & Khaleel, R. A. (2023) · Drug development & registration · doi:10.33380/2305-2066-2023-12-1-52-58 · Cited by 8
Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis
Akepati, P. R., & Gochanour, E. M. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2348743 · Cited by 8
“Filling in these treatment needs, Obeticholic acid (OCA), a potent Farnesoid X receptor (FXR) agonist [19], has established itself as the second-line medication for patients with inadequate biochemical response to UDCA.”
BackgroundMagnesium chenoursodeoxycholic acid ameliorates carbon tetrachloride-induced liver fibrosis in rats
Kang, J., Yoon, S., Sung, Y.-K., & Lee, S. (2011) · Experimental Biology and Medicine · doi:10.1258/ebm.2011.011219 · Cited by 6
Tanaka, A., Leung, P. S. C., Young, H. A., & Gershwin, M. E. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.70995 · Cited by 7
“Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.”
BackgroundInfluentialChronic activation of FXR-induced liver growth with tissue-specific targeting Cyclin D1
Wu, W., Wu, Q., & Liu, X.-M. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1634955 · Cited by 6
Ishida, C., Sanoh, S., & Kotake, Y. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.08.021 · Cited by 6
Zhao, S., Peng, W., Li, X., Wang, L., Yin, W., Wang, Y., Hou, R., & Chen, W. (2021) · RSC Advances · doi:10.1039/d0ra09320c · Cited by 7
Merk, D., Grisoni, F., Schaller, K., Friedrich, L., & Schneider, G. (2018) · ChemistryOpen · doi:10.1002/open.201800156 · Cited by 6
Ma, H., Bao, Y., Niu, S., Wang, S., Li, Y., He, H., Zhang, N., & Fang, W. (2023) · Pharmaceuticals · doi:10.3390/ph16050758 · Cited by 6
An update on novel pharmacological agents for primary sclerosing cholangitis
Gallo, C., Howardson, B. O., Cristoferi, L., Carbone, M., Gershwin, M. E., & Invernizzi, P. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2030707 · Cited by 6
Hu, M., Pan, Y. F., Zhou, H.-G., Zhou, H., & Tang, L.-J. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s78496 · Cited by 6
ATVB In Focus: Novel Approaches to the Treatment of Dyslipidemia
Rader, D. J. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000154483.28595.a3 · Cited by 7
Strassburg, C. P., & Kalthoff, S. (2012) · Wiley eBooks · doi:10.1002/9783527630905.ch3 · Cited by 6
Bile Acids as Signaling Molecules
Claudel, T., & Trauner, M. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch25 · Cited by 9
Kim, E. Y., & Lee, J. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125825 · Cited by 8
“These advances culminated in the development of obeticholic acid (OCA/INT-747), a semi-synthetic 6 α -ethyl-CDCA analog, approved for primary biliary cholangitis (PBC), a hepatic autoimmune disease leading to inflammation and destruction of the bile ducts [146–150].”
Wang, W., Cao, Z., Yang, Z., Chen, Y., Yao, H., Zhou, D., Ou, P., Huang, W., Jiao, S., Chen, S., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115614 · Cited by 5
SecureFIA: Secure Federated Image Authentication Intelligent System for Smart Cities
Yu, H., Zhang, J., Li, Z., Feng, H., Liu, B., Jiang, R., & Yao, Y. (2024) · IEEE Transactions on Consumer Electronics · doi:10.1109/tce.2024.3416513 · Cited by 5
Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis
Esteban, J. P., & Asgharpour, A. (2020) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2019.10.003 · Cited by 5
Metadata
- Authors
- Pellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M.
- Affiliations
- University of Perugia (IT)
- Corresponding author
- Pellicciari, Roberto
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2002-07-20
- Volume
- 45
- Issue
- 17
- Pages
- 3569-3572
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2049515100
- Cited by
- 743
- References
- 15
- Citations by year
- 2026: 20 · 2025: 33 · 2024: 32 · 2023: 33 · 2022: 46 · 2021: 47 · 2020: 54 · 2019: 46 · 2018: 52 · 2017: 60 · 2016: 49 · 2015: 38 · 2014: 35 · 2013: 27 · 2012: 31
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- farnesoid X receptor agonist, cholestasis, bile acid synthesis inhibition, receptor selectivity
- MeSH terms
- Receptor, Farnesoid X-Activated, Animals, Anticholesteremic Agents, Cell Line, Chenodeoxycholic Acid, Cholestasis, DNA-Binding Proteins, Humans, Ligands, Liver, Structure-Activity Relationship, Transcription Factors, Rats, Wistar, Receptors, Cytoplasmic and Nuclear, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.